ID 657 -
Fenyloalanina
PL: Fenyloalanina
EN: L-phenylalanine
Pdf: L-phenylalanine
Oświadczenie (2)
- zwiększenie aktywności endorfins
1. Charakterystyka żywności / składnika
The food constituent that is the subject of the health claims is phenylalanine.
L-phenylalanine is an essential amino acid and can be measured in food by established methods. It occurs naturally in foods, particularly protein-rich foods such as meat, fish and dairy products as a constituent of the proteins.
The Panel considers that the food constituent, L-phenylalanine, which is the subject of the health claims, is sufficiently characterised.
2.2. Poprawa nastroju (ID 657)
The claimed effect is “increase activity of endorfins”. The Panel assumes that the target population is the general population.
In the context of the proposed wordings and the clarifications provided by Member States, the Panel assumes that the claimed effect refers to mood enhancement.
Enhancement of mood is measurable by established methods.
The Panel considers that enhancement of mood might be a beneficial physiological effect.
2.3. Uśmierzanie bólu (ID 657)
The claimed effect is “increase activity of endorfins”. The Panel assumes that the target population is the general population.
In the context of the proposed wordings and the clarifications provided by Member States, the Panel assumes that the claimed effect refers to pain relief.
Pain relief is measurable by established methods.
The Panel considers that pain relief is a beneficial physiological effect.
3.2. Poprawa nastroju (ID 657)
A total of four references were provided to substantiate the claimed effect, including one narrative review, two human studies and one animal study.
The Panel notes that the narrative review (Russell and McCarty, 2000) and the animal study (Halpern and Dong, 1986) reported on outcomes associated with pain relief rather than mood. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claimed effect.
The two human studies were on DL-phenylalanine effects on the treatment of patients with depression. The Fischer et al. (1975) study was an uncontrolled therapeutic study on patients with endogenous depression who had previously undergone unsuccessful treatment with common anti- depressant drugs. The Beckman et al. (1977) study was an uncontrolled therapeutic study on depressed patients. The Panel notes that no conclusions can be drawn from these references for the scientific substantiation of the claimed effect.
The Panel concludes that a cause and effect relationship has not been established between the dietary intake of L-phenylalanine and enhancement of mood.
3.3. Uśmierzanie bólu (ID 657)
A total of four references were provided to substantiate the claimed effect, including one narrative review, two human studies and one animal study.
The Panel notes that the two human studies (Fischer et al., 1975; Beckman et al., 1977) investigated the effect of DL-phenylalanine on the treatment of patients with depression rather than pain relief. The Panel considers that no conclusions could be drawn from these references for the scientific substantiation of the claimed effect.
The Panel notes that the narrative review (Russell and McCarty, 2000) did not provide primary scientific data that could be used to substantiate the claimed effect. The animal study of Halpern and Dong (1986) showed that D-phenylalanine had no significant effect in a primate acute pain model.
The Panel concludes that a cause and effect relationship has not been established between the dietary intake of L-phenylalanine and pain relief.
Warunki i możliwe ograniczenia stosowania oświadczenia
500 -1000 mg per day, Not recommended for people suffering from fenylketonuria